Statin use and risk of kidney cancer: A meta-analysis of observational studies and randomized trials

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 458-465

  Zhang, Xiao Long ^a,b   Liu, Min ^a,b   Qian, Jian ^c   Zheng, Jun Hua ^a,b   Zhang, Xiao Peng ^a,b   Guo, Chang Cheng ^a   Geng, Jiang ^a,b   Peng, Bo ^a,b   Che, Jian Ping ^a   Wu, Yan ^b  

^a TONGJI UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c TAIXING PEOPLE'S HOSPITAL   (China)

Author keywords

kidney cancer; meta analysis; risk; statin

Indexed keywords

KIDNEY CANCER; META-ANALYSIS; RISK; STATIN;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY NEOPLASMS; OBSERVATIONAL STUDY AS TOPIC; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84894471681     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12210     Document Type: Review

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. World Health Organization Cance Stats Cancer worldwide. Available at http://info.cancerresearchuk.org/cancerstats/world/ (last accessed 22 January 2011).
3. National Cancer Institute SEER stat fact sheets: kidney and renal pelvis. Available at http://seer.cancer.gov/statfacts/html/urinb.html (last accessed 22 January 2011).
4. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D,. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769-1781.
5. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C,. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
6. Newman TB, Hulley SB,. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60.
7. Keyomarsi K, Sandoval L, Band V, Pardee AB,. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-3609.
8. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S,. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002; 4: 337-346.
9. Wong WW, Dimitroulakos J, Minden MD, Penn LZ,. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-519.
10. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB,. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-150.
11. Weis M, Heeschen C, Glassford AJ, Cooke JP,. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745.
12. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE,. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50: 83-93.
13. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H,. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-317.
14. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M,. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 8648-8655.
15. Woodard J, Sassano A, Hay N, Platanias LC,. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008; 14: 4640-4649.
16. Chiu HF, Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY,. Statin use and the risk of kidney cancer: a population-based case-control study. Expert Opin Drug Saf 2012; 11: 543-549.
17. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM,. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001; 10: 971-981.
18. Coogan PF, Rosenberg L, Strom BL,. Statin use and the risk of 10 cancers. Epidemiology 2007; 18: 213-219.
19. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005; 3: 6.
20. Hippisley-Cox J, Coupland C,. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340: c2197.
21. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM,. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011; 71: 1763-1771.
22. Kaye JA, Jick H,. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-637.
23. Liu W, Choueiri TK, Cho E,. Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. Cancer 2011; 118: 797-803.
24. Sato S, Ajiki W, Kobayashi T, Awata N, PCS Study Group. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 2006; 16: 201-206.
25. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA,. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008; 17: 27-36.
26. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ,. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394.
27. Khurana V, Caldito G, Ankem M,. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008; 71: 118-122.
28. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
30. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
31. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
32. Undela K, Srikanth V, Bansal D,. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012; 135: 261-269.
33. Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, Shi M, Li W, Zheng H, Jiang B,. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 2012; 23: 1099-1111.
34. Pradelli D, Soranna D, Scotti L, Zambon A, Catapano A, Mancia G, La Vecchia C, Corrao G,. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev 2013; 22: 229-234.
35. Browning DR, Martin RM,. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120: 833-843.
36. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM,. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74-80.
37. Cholesterol Treatment Trialists' (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C,. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7: e29849.
38. Kuoppala J, Lamminpää A, Pukkala E,. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
39. Hamelin BA, Turgeon J,. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26-37.
40. Rogers MJ,. Statins: lower lipids and better bones? Nat Med 2000; 6: 21-23.
41. Goldstein MR, Mascitelli L, Pezzetta F,. The double-edged sword of statin immunomodulation. Int J Cardiol 2009; 135: 128-130.
42. Lee KJ, Moon JY, Choi HK, Kim HO, Hur GY, Jung KH, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Yoo SH, Kang KH, Lee SY,. Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol 2010; 161: 298-305.
43. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008; 197: 829-839.
44. Raemer PC, Kohl K, Watzl C,. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009; 39: 1456-1465